Info

Dynogen is a clinical stage biopharmaceutical company developing more effective treatments for gastrointestinal (GI) and genitourinary (GU) disorders. The Company has an advanced pipeline of clinical development programs focused on attractive and untapped markets in disease areas that severely impair a patient's quality of life, such as irritable bowel syndrome (IBS), nocturnal gastroesophageal reflux disease (NGERD) and overactive bladder (OAB). In 2007, Dynogen generated positive clinical proof of concept data for three of its development programs:Positive Phase 2a results for DDP733 as a treatment for IBS-c; Positive Phase 2a results for DDP225 as a treatment for IBS-d; Positive Phase 1b results for DDP733 as a treatment for NGERD. Dynogen's clinical pipeline also includes two GU programs: Dynogen is planning a Phase 2b study of DDP200 as a treatment for OAB. DDP225 is ready for Phase 2 development as a treatment for OAB. In building a portfolio, Dynogen is increasing its likelihood for clinical success in the development process by focusing on product candidates with known safety and pharmacokinetic profiles, determined dose ranging, and early evidence of efficacy. Two of Dynogen's compounds, DDP733 and DDP225, have already been clinically tested in more than 400 human subjects each. In these studies, both DDP733 and DDP225 were well tolerated. The GI and GU markets represent attractive opportunities for drug development. In 2005, worldwide pharmaceutical sales for the GI and GU markets were estimated at $20 billion and $5 billion respectively. Both markets include disorders affecting millions of patients with significant unmet needs. Dynogen believes that these markets are under-served in terms of prescription drug sales compared to other disorders.